Expedited Pharmacogenomics

摘要

Drug-induced liver injury is one of the most common reasons that approved drugs are recalled from the market and that clinical trials of experimental drugs are terminated early. Susceptibility to liver damage and other adverse drug reactions are in part genetically determined, and a major goal of pharmacogenomics research is to find genetic markers that can be used to identify at-risk individuals in advance of drug treatment. The search for such biomarkers in human populations has proven to be labor-intensive, but a new study suggests that the hunt can be streamlined by using data derived from genetically diverse mouse populations to guide the human studies.